American Shared Hospital Services (AMS) 10-K 28 Mar 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 20, 2018	Jun. 30, 2017
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Registrant Name	AMERICAN SHARED HOSPITAL SERVICES
Entity Central Index Key	744,825
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 14,249,000
Trading Symbol	AMS
Entity Common Stock, Shares Outstanding		5,710,000

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2017	Dec. 31, 2016
CURRENT ASSETS
Cash and cash equivalents	$ 2,152,000	$ 2,871,000
Restricted cash	350,000	250,000
Trade accounts receivable, net of allowance for doubtful accounts of $100,000 at December 31, 2017 and December 31, 2016	5,019,000	4,085,000
Other receivables	216,000	290,000
Prepaid expenses and other current assets	1,156,000	370,000
Total current assets	8,893,000	7,866,000
PROPERTY AND EQUIPMENT, net	48,491,000	51,331,000
INVESTMENT IN EQUITY SECURITIES	0	579,000
OTHER ASSETS	792,000	822,000
TOTAL ASSETS	58,176,000	60,598,000
CURRENT LIABILITIES
Accounts payable	359,000	319,000
Employee compensation and benefits	187,000	184,000
Other accrued liabilities	1,188,000	1,100,000
Current portion of long-term debt	2,459,000	2,205,000
Current portion of capital leases	4,814,000	4,873,000
Total current liabilities	9,007,000	8,681,000
LONG-TERM DEBT, less current portion	3,598,000	5,106,000
LONG-TERM CAPITAL LEASES, less current portion	12,272,000	14,852,000
DEFERRED REVENUE, less current portion	504,000	610,000
DEFERRED INCOME TAXES	2,910,000	4,176,000
COMMITMENTS AND CONTINGENCIES (See Note 11)
SHAREHOLDERS’ EQUITY
Common stock, no par value (10,000,000 authorized; Issued and outstanding shares - 5,710,000 at December 31, 2017 and 5,468,000 at December 31, 2016	10,711,000	10,596,000
Additional paid-in capital	6,272,000	5,949,000
Retained earnings	6,873,000	4,950,000
Total equity- American Shared Hospital Services	23,856,000	21,495,000
Non-controlling interests in subsidiaries	6,029,000	5,678,000
Total shareholders' equity	29,885,000	27,173,000
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 58,176,000	$ 60,598,000

CONSOLIDATED BALANCE SHEETS _Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Allowance for doubtful accounts (in dollars)	$ 100,000	$ 100,000
Common stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	5,710,000	5,468,000
Common stock, shares outstanding	5,710,000	5,468,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue:
Rental income from medical services	$ 19,556,000	$ 18,700,000	$ 16,548,000
Revenue	19,556,000	18,700,000	16,548,000
Costs of revenue:
Maintenance and supplies	1,359,000	874,000	1,089,000
Depreciation and amortization	6,601,000	6,262,000	6,139,000
Other direct operating costs	2,933,000	2,769,000	2,605,000
Costs of revenue	10,893,000	9,905,000	9,833,000
Gross margin	8,663,000	8,795,000	6,715,000
Selling and administrative expense	4,323,000	3,802,000	3,496,000
Interest expense	1,927,000	1,707,000	1,239,000
Operating income	2,413,000	3,286,000	1,980,000
(Loss) on early extinguishment of debt	0	(108,000)	0
(Loss) on write down investment in equity securities	(579,000)	0	(2,140,000)
Interest and other income	3,000	15,000	18,000
Income before income taxes	1,837,000	3,193,000	(142,000)
Income tax (benefit) expense	(1,103,000)	943,000	434,000
Net income (loss)	2,940,000	2,250,000	(576,000)
Less: net income attributable to non-controlling interests	(1,017,000)	(1,320,000)	(946,000)
Net income (loss) attributable to American Shared Hospital Services	$ 1,923,000	$ 930,000	$ (1,522,000)
Net income (loss) per share attributable to American Shared Hospital Services:
Income (loss) per common share- basic	$ 0.33	$ 0.17	$ (0.28)
Income (loss) per common share- diluted	$ 0.33	$ 0.17	$ (0.28)

CONSOLIDATED STATEMENT OF SHARE

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Sub-Total ASHS [Member]	Non-controlling Interest [Member]
Balances at Dec. 31, 2014	$ 26,154,000	$ 10,376,000	$ 5,508,000	$ 5,542,000	$ 21,426,000	$ 4,728,000
Balances (in shares) at Dec. 31, 2014		5,361,000
Stock-based compensation expense	226,000	$ 0	226,000	0	226,000	0
Stock-based compensation expense (in shares)		3,000
Non-controlling interest investment in subsidiaries	46,000	$ 0	0	0	0	46,000
Cash distributions to non-controlling interests	(670,000)	0	0	0	0	(670,000)
Net (loss) income	(576,000)	0	0	(1,522,000)	(1,522,000)	946,000
Balances at Dec. 31, 2015	25,180,000	$ 10,376,000	5,734,000	4,020,000	20,130,000	5,050,000
Balances (in shares) at Dec. 31, 2015		5,364,000
Stock-based compensation expense	215,000	$ 0	215,000	0	215,000	0
Stock-based compensation expense (in shares)		4,000
Proceeds from warrants exercised	220,000	$ 220,000	0	0	220,000	0
Proceeds from warrants exercised (in shares)		100,000
Non-controlling interest investment in subsidiaries	7,000	$ 0	0	0	0	7,000
Cash distributions to non-controlling interests	(699,000)	0	0	0	0	(699,000)
Net (loss) income	2,250,000	0	0	930,000	930,000	1,320,000
Balances at Dec. 31, 2016	27,173,000	$ 10,596,000	5,949,000	4,950,000	21,495,000	5,678,000
Balances (in shares) at Dec. 31, 2016		5,468,000
Stock-based compensation expense	$ 323,000	$ 0	323,000	0	323,000	0
Stock-based compensation expense (in shares)		4,000
Proceeds from warrants exercised (in shares)	25,000
Restricted stock awards	$ 0	$ 0	0	0	0	0
Restricted stock awards (in shares)		162,000
Warrants and options exercised	115,000	$ 115,000	0	0	115,000	0
Warrants and options exercised (in shares)		76,000
Cash distributions to non-controlling interests	(666,000)	$ 0	0	0	0	(666,000)
Net (loss) income	2,940,000	0	0	1,923,000	1,923,000	1,017,000
Balances at Dec. 31, 2017	$ 29,885,000	$ 10,711,000	$ 6,272,000	$ 6,873,000	$ 23,856,000	$ 6,029,000
Balances (in shares) at Dec. 31, 2017		5,710,000

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
OPERATING ACTIVITIES
Net income (loss)	$ 2,940,000	$ 2,250,000	$ (576,000)
Adjustments to reconcile net income (loss) to net cash from operating activities:
Depreciation and amortization	6,677,000	6,327,000	6,190,000
Loss on disposal of assets	15,000	0	0
Loss on early extinguishment of debt	0	108,000	0
Loss on write down investment in equity securities	579,000	0	2,140,000
Amortization of accrued interest on lease financing	80,000	0	0
Deferred income tax (benefit) expense	(1,266,000)	772,000	298,000
Accrued interest on lease financing	33,000	414,000	0
Stock-based compensation expense	323,000	215,000	226,000
Other non-cash items	0	4,000	(31,000)
Changes in operating assets and liabilities:
Receivables	(860,000)	(1,230,000)	178,000
Prepaid expenses and other assets	(793,000)	(283,000)	(52,000)
Accounts payable, accrued liabilities and deferred revenue	125,000	(199,000)	175,000
Net cash from operating activities	7,853,000	8,378,000	8,548,000
INVESTING ACTIVITIES
Payment for purchase of property and equipment	(803,000)	(1,042,000)	(900,000)
Investment in equity securities	0	0	(10,000)
Proceeds from sale of equipment	150,000	0	0
Net cash (used in) investing activities	(653,000)	(1,042,000)	(910,000)
FINANCING ACTIVITIES
Principal payments on long-term debt	(2,314,000)	(2,968,000)	(2,058,000)
Principal payments on capital leases	(4,954,000)	(4,171,000)	(4,026,000)
Proceeds from certificate of deposit	0	0	9,000,000
Payments on line of credit	0	0	(8,780,000)
Capital contributions from non-controlling interests	0	7,000	46,000
Distributions to non-controlling interests	(666,000)	(699,000)	(670,000)
Proceeds from warrants and options exercised	115,000	220,000	0
Proceeds from capital lease financing for reimbursement of payments for acquisition of equipment	0	1,137,000	0
Reclassification of restricted cash	(100,000)	(200,000)	0
Net cash (used in) financing activities	(7,919,000)	(6,674,000)	(6,488,000)
Net change in cash and cash equivalents	(719,000)	662,000	1,150,000
CASH AND CASH EQUIVALENTS, beginning of year	2,871,000	2,209,000	1,059,000
CASH AND CASH EQUIVALENTS, end of year	2,152,000	2,871,000	2,209,000
SUPPLEMENTAL CASH FLOW DISCLOSURE
Cash paid for interest	1,712,000	2,150,000	1,670,000
Cash paid for income taxes	126,000	266,000	25,000
SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES
Acquisition of equipment with capital lease financing	2,153,000	8,878,000	1,343,000
Acquisition of equipment with long-term debt financing	$ 992,000	$ 570,000	$ 1,016,000

BUSINESS AND BASIS OF PRESENTAT

BUSINESS AND BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 – Business and Basis of Presentation Business – The Company (through ASRS) and Elekta AB, the manufacturer of the Gamma Knife (through its wholly-owned United States subsidiary, GKV Investments, Inc.), entered into an operating agreement and formed GK Financing, LLC. During 2017 GKF provided Gamma Knife units to nineteen medical centers in the United States in the states of Arkansas, California, Connecticut, Florida, Illinois, Massachusetts, Mississippi, Nebraska, Nevada, New Jersey, New Mexico, New York, Tennessee, Oklahoma, Ohio, Oregon and Texas. The Company through its wholly-owned subsidiary, Orlando, provided proton beam radiation therapy (“PBRT”) and related equipment to a customer in the United States. The Company also directly provides radiation therapy and related equipment, including Intensity Modulated Radiation Therapy (“IMRT”), Image Guided Radiation Therapy (“IGRT”) and a CT Simulator to the radiation therapy department at an existing Gamma Knife site in Massachusetts. The Company formed the subsidiaries GKPeru and GKUK for the purposes of expanding its business internationally into Peru and the United Kingdom, respectively; Orlando and LBE to provide proton beam therapy equipment and services in Orlando, Florida and Long Beach, California; and AGKE and JGKE to provide Gamma Knife equipment and services in Albuquerque, New Mexico and Jacksonville, Florida, respectively. AGKE began operations in the second quarter of 2011 and JGKE began operations in the fourth quarter of 2011. Orlando treated its first patient in April 2016. GKPeru treated its first patient in July 2017. GKUK is inactive and LBE is not expected to generate revenue within the next two years. The Company continues to develop its design and business model for “The Operating Room for the 21st Century” SM MedLeader was formed to provide continuing medical education online and through videos for doctors, nurses, and other healthcare workers. This subsidiary is not operational at this time. All significant intercompany accounts and transactions have been eliminated in consolidation.

ACCOUNTING POLICIES

ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2 – Accounting Policies Use of estimates in the preparation of financial statements Advertising costs Cash and cash equivalents Restricted cash Business and credit risk All of the Company’s revenue was provided by twenty, eighteen, and seventeen customers in 2017, 2016, and, 2015, and these customers constitute accounts receivable at December 31, 2017 and 2016, respectively. One customer accounted for approximately 21%, 10%, and 10% of the Company’s total revenue in 2017, 2016 and 2015, respectively. At December 31, 2017 and 2016, three and two customers each accounted for more than 10% of total accounts receivable, respectively. The Company performs credit evaluations of its customers and generally does not require collateral. The Company has not experienced significant losses related to receivables from individual customers or groups of customers in any particular geographic area. All of the Company’s radiosurgery devices have been purchased through Elekta, to date. However, there are other manufacturers that also make radiosurgery devices. All of the Company’s revenue was provided by twenty, eighteen, and seventeen customers in 2017, 2016, and, 2015, and these customers constitute accounts receivable at December 31, 2017 and 2016, respectively. One customer accounted for approximately 21%, 10%, and 10% of the Company’s total revenue in 2017, 2016 and 2015, respectively. At December 31, 2017 and 2016, three and two customers each accounted for more than 10% of total accounts receivable, respectively. The Company performs credit evaluations of its customers and generally does not require collateral. The Company has not experienced significant losses related to receivables from individual customers or groups of customers in any particular geographic area. All of the Company’s radiosurgery devices have been purchased through Elekta, to date. However, there are other manufacturers that also make radiosurgery devices. Accounts receivable and doubtful accounts Non-controlling interests Property and equipment The Company adopted a new accounting policy for the depreciation of PBRT property and equipment. Depreciation is determined using the modified units of production method, which is a function of both time and usage of the equipment. This depreciation method allocates costs considering the projected volume of usage through the useful life of the PBRT unit, which has been estimated at 20 years. The estimated useful life of the PBRT unit is consistent with the estimated economic life of 20 years. The Company capitalizes interest incurred on property and equipment that is under construction, for which deposits or progress payments have been made. When a rate is not readily available, imputed interest is calculated using the Company’s incremental borrowing rate. The interest capitalized for property and equipment is the portion of interest cost incurred during the acquisition periods that could have been avoided if expenditures for the equipment had not been made. The Company capitalized interest of $138,000, $443,000, and $431,000 in 2017, 2016, and 2015, respectively, as costs of medical equipment. The Company leases Gamma Knife and radiation therapy equipment to its customers under arrangements typically accounted for as operating leases. At December 31, 2017, the Company held equipment under operating lease contracts with customers with an original cost of $95,923,000 and accumulated depreciation of $51,403,000. At December 31, 2016, the Company held equipment under operating lease contracts with customers with an original cost of $96,270,000 and accumulated depreciation of $53,306,000. In April 2017, an existing customer exercised their option to purchase the Gamma Knife unit at its hospital at the end of the lease term for a predetermined purchase price, pursuant to the lease agreement. The lease terminated in April 2017, at which time, the unit was depreciated to the purchase price of the sale. Based on the guidance provided in ASC 360 Property, Plant and Equipment (“ASC 360”), the Company did not classify or measure the asset as held for sale prior to the lease termination, because the Gamma Knife unit was not available for immediate sale. Investment in equity securities – Fair value of financial instruments The estimated fair value of the Company’s assets and liabilities as of December 31, 2017 and December 31, 2016 were as follows (in thousands): Level 1 Level 2 Level 3 Total Carrying December 31, 2017 Assets: Cash, cash equivalents, restricted cash $ 2,502 $ - $ - $ 2,502 $ 2,502 Investment in equity securities - - - - - Total $ 2,502 $ - $ - $ 2,502 $ 2,502 Liabilities Debt obligations $ - $ - $ 6,082 $ 6,082 $ 6,057 Total $ - $ - $ 6,082 $ 6,082 $ 6,057 December 31, 2016 Assets: Cash, cash equivalents, restricted cash $ 3,121 $ - $ - $ 3,121 $ 3,121 Investment in equity securities - - 579 579 579 Total $ 3,121 $ - $ 579 $ 3,700 $ 3,700 Liabilities Debt obligations $ - $ - $ 7,354 $ 7,354 $ 7,311 Total $ - $ - $ 7,354 $ 7,354 $ 7,311 - Rental income from medical services is recognized when services have been rendered and collectability is reasonably assured, on either a fee per use or revenue sharing basis. The terms of the contracts do not contain any guaranteed minimum payments. The Company’s contracts are typically for a ten year term and are classified as either fee per use or retail. Retail arrangements are further classified as either turn-key or revenue sharing. Rental income from fee per use contracts is determined by each hospital’s contracted rate. Rental income is recognized at the time the procedures are performed, based on each hospital’s contracted rate and the number of procedures performed. Under revenue sharing arrangements, the Company receives a contracted percentage of the reimbursement received by the hospital. The amount the Company expects to receive is recorded as revenue and estimated based on historical experience. Rental income estimates are reviewed periodically and adjusted as necessary. Under turn-key arrangements, the Company receives payment from the hospital in the amount of its reimbursement from third party payors, and the Company is responsible for paying all the operating costs of the equipment. Operating costs are determined primarily based on historical treatment protocols and cost schedules with the hospital. The Company records an estimate of operating costs which are reviewed on a regular basis and adjusted as necessary to more accurately reflect the actual operating costs. For turn-key sites, the Company also shares a percentage of net operating profit. The Company records an estimate of net operating profit based on estimated revenues, less estimated operating costs. The operating costs and estimated net operating profit are recorded as other direct operating costs in the consolidated statement of operations. Stock-based compensation Costs of revenue – Sales and Marketing Income taxes Functional currency Foreign Currency Matters Asset Retirement Obligations Earnings per share The following table illustrates the computations of basic and diluted earnings per share for the years ended December 31, 2017, 2016 and 2015. 2017 2016 2015 Numerator for basic and diluted earnings (loss) per share $ 1,923,000 $ 930,000 $ (1,522,000 ) Denominator: Denominator for basic and diluted earnings (loss) per share – weighted-average shares 5,754,000 5,570,000 5,519,000 Effect of dilutive securities Employee stock options and restricted stock 130,000 13,000 - Denominator for diluted earnings (loss) per share – adjusted weighted- average shares 5,884,000 5,583,000 5,519,000 Earnings (loss) per common share- basic $ 0.33 $ 0.17 $ (0.28 ) Earnings (loss) per common share- diluted $ 0.33 $ 0.17 $ (0.28 ) In 2017, options outstanding to purchase 14,000 shares of common stock at an exercise price range of $3.90 per share and 4,000 restricted stock units were not included in the calculation of diluted earnings per share because they would be anti-dilutive. In 2016, options outstanding to purchase 581,000 shares of common stock at an exercise price range of $2.43 - $3.15 per share and 4,000 restricted stock units were not included in the calculation of diluted earnings per share because they would be anti-dilutive. In 2015, options outstanding to purchase 614,000 shares of common stock at an exercise price range of $2.05 - $3.15 per share, 3,000 restricted stock units and warrants to purchase 200,000 shares of common stock, issued with promissory notes, at an exercise price of $2.20, were not included in the calculation of diluted earnings per share because they would be anti-dilutive. Business segment information - Based on the guidance provided in accordance with ASC 280 Segment Reporting The Company did not have any international operations as of December 31, 2016, but the Company’s single-unit facility in Peru treated its first patient in July 2017. The following table provides a break out of domestic and foreign allocations of medical services revenues and net property and equipment: 2017 2016 2015 Medical services revenues Domestic 99 % 100 % 100 % Foreign 1 % 0 % 0 % Total 100 % 100 % 100 % 2017 2016 2015 Property and equipment, net Domestic 93 % 93 % 93 % Foreign 7 % 7 % 7 % Total 100 % 100 % 100 % Long lived asset impairment Recently issued and adopted accounting pronouncements Revenue from Contracts with Customers Technical Corrections and Improvements to Topic 606 Leases In January 2016, the FASB issued ASU No. 2016-01 Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, which requires lessees to recognize, for all leases, at the commencement date, a lease liability, and a right-of-use asset. Under the new guidance, lessor accounting is largely unchanged. The new guidance is effective for the Company on January 1, 2019. Early adoption is permitted. The Company is evaluating the effect that ASU 2016-02 will have on its consolidated financial statements and related disclosures. The Company performed an analysis to determine if its revenue agreements with customers fall under the scope of ASU 2016-02 or ASU 2014-09 and concluded that, other than with respect to the Company’s stand-alone facility in Lima, Peru, ASU 2016-02 applied. The Company believes it is following an appropriate timeline to allow for proper recognition, presentation, and disclosure upon adoption of ASU 2016-02. In March 2016, the FASB issued ASU No. 2016-09 Compensation – Stock Compensation (Topic 718) In June 2016, the FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2016, the FASB issued ASU No. 2016-15 Statement of Cash Flows (Topic 230) – Classification of Certain Cash Receipts and Cash Payments In November 2016, the FASB issued ASU No. 2016-18 Statement of Cash Flows – Restricted Cash In May 2017, the FASB issued ASU No. 2017-09 Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting Reclassifications

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 3 – Property and Equipment DECEMBER 31, 2017 2016 Medical equipment and facilities $ 95,923,000 $ 96,270,000 Office equipment 576,000 537,000 Deposits and construction in progress 1,658,000 6,073,000 Deposits towards purchase of proton beam systems 2,000,000 2,000,000 100,157,000 104,880,000 Accumulated depreciation (51,666,000) (53,549,000) Net property and equipment $ 48,491,000 $ 51,331,000 The Company has equipment that is secured under capitalized leases, which is included in Medical equipment and facilities, with a total cost of $ 44,758,000 16,777,000 43,703,000 16,642,000 729,000 As of December 31, 2017, the Company has $ 1,658,000 As of December 31, 2017, the Company has $ 2,000,000 400,000

INVESTMENT IN EQUITY SECURITIES

INVESTMENT IN EQUITY SECURITIES	12 Months Ended
	Dec. 31, 2017
Investments, All Other Investments [Abstract]
Cost-method Investments, Description [Text Block]	Note 4 – Investment in Equity Securities As of December 31, 2017, the Company recognized no value for its investment in the common stock of Mevion Medical Systems, Inc. (“Mevion”), formerly Still River Systems, representing an approximate 0.46 579 Based on guidance provided in ASC 320 Investments–Debt and Equity Securities Topic 5M Other Than Temporary Impairment (“OTTI”) of Certain Investments in Equity Securities 600,000 2,114,000 2,114,000 During the period ended December 31, 2015, the Company engaged a third party expert to review and corroborate its assessment of the fair value of the Mevion investment. The third party utilized the market approach and an option waterfall model calibrated to Mevion’s last round of funding. Each equity class was examined and priced according to its liquidation preferences. Based on the third party analysis, an additional impairment loss of $ 26,000 579,000 2,140,000 During the year ended December 31, 2017, the Company reviewed its investment in Mevion and determined the fair value of its investment was $ 0 579

LONG-TERM DEBT

LONG-TERM DEBT	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Long-term Debt [Text Block]	Note 5 – Long-Term Debt Long-term debt consists primarily of eight notes with three financing companies collateralized by the Gamma Knife equipment having an aggregate net book value of $ 15,125,000 These notes are payable in 36 to 81 fully amortizing monthly installments, mature between December 2018 and November 2021 3.95 7.48 Principal Interest Year ending December 31, 2018 $ 2,459,000 $ 301,000 2019 1,988,000 163,000 2020 1,146,000 61,000 2021 464,000 13,000 $ 6,057,000 $ 538,000

OBLIGATIONS UNDER CAPITAL LEASE

OBLIGATIONS UNDER CAPITAL LEASES	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Debt and Capital Leases Disclosures [Text Block]	Note 6 – Obligations Under Capital Leases The Company has twelve capital lease obligations with four financing companies, collateralized by Gamma Knife and PBRT equipment having an aggregate net book value of $ 27,981,000 4.73 13.00 payable in 41 to 84 monthly installments, and mature between September 2018 and October 2024. 27,061,000 Net Present Value of Minimum Lease Payments Year ending December 31, 2018 $ 6,113,000 2019 4,550,000 2020 3,280,000 2021 5,453,000 2022 629,000 Thereafter 719,000 Total capital lease payments 20,744,000 Less imputed interest 3,658,000 17,086,000 Less current portion 4,814,000 $ 12,272,000

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 7 – Income Taxes As of December 31, 2017, 2016 and 2015 the Company recorded income tax provision benefit of $ 1,103,000 943,000 434,000 21 34 1,546,000 The increase in the Company’s provision for income taxes as of December 31, 2016 is due to income from the PBRT system and operations of the Company’s subsidiaries. The increase in the Company’s provision for income taxes as of December 31, 2015 is due to income from operations of the Company’s subsidiaries. The loss incurred during the year ended December 31, 2015 on the write-down of the Company’s investment in equity securities is a capital loss which is treated as non-deducible expense for income tax provision purposes and as such, a full valuation allowance was recorded against this loss and the net impact to the provision was $ 0 YEARS ENDED DECEMBER 31, 2017 2016 2015 Current: Federal $ 55,000 $ 24,000 $ 35,000 State 109,000 146,000 103,000 Total current 164,000 170,000 138,000 Deferred: Federal (1,335,000) 680,000 353,000 State 68,000 93,000 (57,000) Total deferred (1,267,000) 773,000 296,000 $ (1,103,000) $ 943,000 $ 434,000 DECEMBER 31, 2017 2016 Deferred tax liabilities: Property and equipment $ (5,009,000) $ (7,595,000) Total deferred tax liabilities (5,009,000) (7,595,000) Deferred tax assets: Net operating loss carryforwards 1,421,000 2,783,000 Accruals and allowances 157,000 193,000 Tax credits 438,000 380,000 Other – net 186,000 200,000 Capital loss carryover 959,000 1,228,000 Total deferred tax assets 3,161,000 4,784,000 Valuation allowance (1,062,000) (1,365,000) Deferred tax assets net of valuation allowance 2,099,000 3,419,000 Net deferred tax liabilities $ (2,910,000) $ (4,176,000) DECEMBER 31, 2017 2016 Deferred income taxes (non-current) $ (2,910,000) $ (4,176,000) $ (2,910,000) $ (4,176,000) 34 YEARS ENDED DECEMBER 31, 2017 2016 2015 Computed expected federal income tax $ 279,000 $ 637,000 $ (360,000) State income taxes, net of federal benefit 28,000 169,000 (55,000) Non-deductible expenses 41,000 42,000 40,000 Impact of US Tax Reform (1,546,000) - - Change in valuation allowance 180,000 25,000 792,000 Other (85,000) 70,000 17,000 $ (1,103,000) $ 943,000 $ 434,000 On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”) which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740 Income taxes During the year ended December 31, 2017, the Company did not recognize a provisional income amount for the transition tax, due to the fact the foreign subsidiaries have accumulated losses. The final effects of the Tax Act may differ from these provisional amounts, due to among other things, changes in interpretations of the Tax Act, any legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, any updates or changes to the estimates utilized to calculate provisional amounts, or actions we may take as a result of the Tax Act. The associated accounting for the Tax Act is expected to be completed when our 2017 US corporate income tax return is filed in 2018. At December 31, 2017, the Company has a net operating loss carryforward for federal income tax return purposes of approximately $ 5,928,000 expire between 2024 and 2034 1,137,000 370,000 Utilization of the domestic NOL and tax credit forwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by the Internal Revenue Code Section 382, as well as similar state provisions. In general, an “ownership change,” as defined by the code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 At December 31, 2017, the Company has a capital loss carryforward for federal income tax return purposes of approximately $ 3,895,000 177,000 Due to the uncertainty that the Company will generate capital gains in future years to utilize its capital loss carryforward, a valuation allowance has been placed against the deferred tax asset. Due to uncertainty surrounding the realization of impairment losses, capital losses and foreign operating losses in future years, the Company has placed a valuation allowance against a portion of its net domestic and foreign deferred tax assets. The net valuation allowance decreased by $ 303,000 25,000 792,000 The tax return years 2012 through 2017 remain open to examination by the major domestic taxing jurisdictions to which the Company is subject. Net operating losses generated on a tax return basis by the Company for calendar years 1999 through 2004, 2009, 2010, 2012, 2014, 2015, 2016, and 2017 remain open to examination by the major domestic taxing jurisdictions. The Company has adopted accounting standards which prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company's income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Additionally, these accounting standards specify that tax positions for which the timing of the ultimate resolution is uncertain should be recognized as long-term liabilities. The Company has made no reclassifications between current taxes payable and long term taxes payable under this guidance. Also, the Company had no amounts of unrecognized tax benefits that, if recognized, would affect its effective income tax rate for the years ended December 31, 2017, 2016, and 2015. The Company’s policy for deducting interest and penalties is to treat interest as interest expense and penalties as taxes. As of December 31, 2017, the Company had no amount accrued for the payment of interest and penalties related to unrecognized tax benefits.

SHAREHOLDERS' EQUITY

SHAREHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 8 – Shareholders’ Equity Incentive Compensation Plan In June 2010 shareholders approved an amendment and restatement of the Company’s stock incentive plan, renaming it the Incentive Compensation Plan (the “Plan”), and among other things, increasing the number of shares of the Company’s common stock reserved for issuance under the Plan to 1,630,000 375,000 The Plan provides for nonqualified stock options, qualified (or incentive) stock options and stock grants. The Plan has a provision to reduce the number of shares reserved for award and issuance under the Plan by a ratio of 1.59 The Plan also provides for an Incentive Bonus Program with incentive bonus opportunities through performance unit awards and special cash incentive programs tied to the attainment of pre-established performance milestones. Provisions of the Plan include an automatic annual grant to each non-employee director of options to purchase up to 2,000 500 5 Under the Plan, a total of 241,000 34,000 197,000 10,000 237,000 Restricted Stock Grant Date Intrinsic Value Outstanding at January 1, 2017 4,000 $ 2.25 $ - Granted 22,000 $ 3.47 $ - Vested (22,000) $ 4.06 $ - Forfeited - $ - $ - Outstanding at December 31, 2017 4,000 $ 3.77 $ - For the year ended December 31, 2017, total compensation expense recorded in the consolidated statements of operations related to restricted stock units in lieu of retainer fees was $ 60,000 11,000 4,000 8,000 4,000 4,000 3,000 15,000 8,000 7,000 On January 4, 2017, the Company entered into a Performance Share Award Agreement with three executive officers of the Company (the “Award Agreements”) for 161,766 Stock Compensation 108,000 434,000 129,000 As of December 31, 2016, the Company had warrants outstanding representing the right to purchase 100,000 2.20 100,000 50,000 25,000 Weighted Weighted Average Average Remaining Aggregate Number Exercise Contractual Intrinsic Options of Options Price Term (Years) Value Balance at December 31, 2016 625,000 $ 2.85 4.25 Granted 27,000 $ 3.31 6.66 Exercised (4,000) $ 2.81 - Forfeited (33,000) $ 2.82 - Balance at December 31, 2017 615,000 $ 2.87 3.48 $ 22,000 Exercisable at December 31, 2017 395,000 $ 2.86 3.35 $ - The weighted average grant-date fair value of the options granted during the years 2017, 2016 and 2015 was $ 1.50 0.97 1.15 4,000 144,000 139,000 138,000 The Company received approximately $ 6,000 2,000 Weighted Average Number Grant-Date Nonvested Options of Options Fair Value Nonvested at December 31, 2016 321,000 $ 1.18 Granted 27,000 $ 1.50 Vested (117,000) $ 1.20 Forfeited (11,000) $ 1.27 Nonvested at December 31, 2017 220,000 $ 1.20 At December 31, 2017, there was approximately $ 297,000 The Company’s stock-based awards to employees are calculated using the Black-Scholes options valuation model. The Black-Scholes model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, the Black-Scholes model requires the input of highly subjective assumptions including the expected stock price volatility. The Company’s stock-based awards have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the present value estimates. For these reasons, management believes that the existing models do not necessarily provide a reliable single measure of the fair value of its stock-based awards to employees. The fair value of the Company’s option grants issued during 2017, 2016 and 2015 were estimated using assumptions for expected life, volatility, dividend yield, forfeiture rate, and risk-free interest rate which are specific to each award as summarized in the following table. The estimated fair value of the Company’s options is amortized over the period during which the optionee is required to provide service in exchange for the award, usually the vesting period. 2017 2016 2015 Expected life (years) 7.0 7.0 7.0 Expected forfeiture rate 0.0 % 0.0 % 0.0 % Expected volatility 53 % 53 % 41 % Dividend yield 0 % 0 % 0 % Risk-free interest rate 2.0 % 2.0 % 2.0 % Repurchase of Common Stock, Common Stock Warrants and Stock Options In 1999 and 2001, the Board of Directors approved resolutions authorizing the Company to repurchase up to a total of 1,000,000 72,000

RETIREMENT PLAN

RETIREMENT PLAN	12 Months Ended
	Dec. 31, 2017
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	Note 9 – Retirement Plan The Company has a defined-contribution retirement plan (the “Retirement Plan”) that allows for a matching safe harbor contribution. For 2017, the Board of Directors elected to match participant deferred salary contributions up to a maximum of 4 30,000 27,000

OPERATING LEASES

OPERATING LEASES	12 Months Ended
	Dec. 31, 2017
Leases, Operating [Abstract]
Operating Leases of Lessor Disclosure [Text Block]	Note 10 – Operating Leases The Company leases office space and equipment under operating leases expiring at various dates through 2018 and 2022. On August 13, 2016, the Company entered into a 7 Year ending December 31, 2018 $ 266,000 2019 272,000 2020 245,000 2021 252,000 2022 259,000 Thereafter 165,000 $ 1,459,000 Payments for repair and maintenance agreements incorporated in operating lease agreements are not included in the future minimum operating lease payments shown above. Net rent expense was $ 308,000 307,000 175,000 Total rent expense was recognized net of sublease income of $ 0 76,000 191,000 115,000

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 11 – Commitments and Contingencies As of December 31, 2017, the Company had commitments to purchase two MEVION S250 PBRT systems for $ 25,800,000 2,000,000 On July 21, 2017, the Company signed First Amendments to two System Build Agreements (the “Amendments”) for the Company’s second and third Mevion PBRT units. The Company and Mevion have agreed on preliminary construction and delivery timetables for the second and third PBRT units for which the Company has purchase commitments. The Company’s delivery timeframe is triggered by USFDA 510K clearance of Mevion’s recently developed treatment nozzle. The Company is actively seeking sites for these units but, to date, has not entered into agreements with any party for either placement of a PBRT unit or the related financing. The Company projects that it will be required to take delivery of the second and third PBRT units no later than 2019 and 2020, respectively. In the event the Company is unable to enter into customer agreements within the requisite time frame or receive an extension from Mevion, the Company could forfeit its deposits. On July 21, 2017, the Company entered into a Maintenance and Support Agreement (the “Mevion Service Agreement”) with Mevion, which provides for maintenance and support of the Company’s PBRT unit at Orlando Health. The Mevion Service Agreement began September 5, 2017 and required an upfront payment of $ 1,000,000 As of December 31, 2017, the Company had commitments to perform two Cobtalt-60 reloads at existing Gamma Knife customer sites. Total Gamma Knife commitments as of December 31, 2017 were $ 1,500,000 2018 Thereafter Total Proton Beam Units $ - $ 25,800,000 $ 25,800,000 Gamma Knife Units 1,500,000 - 1,500,000 Total Commitments $ 1,500,000 $ 25,800,000 $ 27,300,000

NOTE, WARRANT, & COMMON STOCK P

NOTE, WARRANT, & COMMON STOCK PURCHASE AGREEMENT	12 Months Ended
	Dec. 31, 2017
Note, Warrant And Common Stock Purchase Agreement [Abstract]
Note, Warrant And Common Stock Purchase Agreement [Text Block]	Note 12 – Note, Warrant, & Common Stock Purchase Agreement In October 2014, the Company entered into a Note and Warrant Purchase Agreement (the “Note and Warrant Purchase Agreement”) with four members of the Company’s Board of Directors to issue an aggregate of $ 1,000,000 200,000 15.0 2.20 100,000 During the year ended December 31, 2016, the Company paid down the Notes. Based on the guidance provided in accordance with ASC 405 Extinguishment of Liabilities Debt Modifications and Extinguishments 108,000 145,000 80,000 28,000 Concurrently with the Note and Warrant Purchase Agreement, the Company entered into a common stock purchase agreement (the “Common Stock Purchase Agreement”) with one member of the Company’s Board of Directors to sell, in a private offering, 100,000 220,000 The Company received gross proceeds of $ 1,220,000 1,000,000

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 13 – Related Party Transactions The Company’s Gamma Knife business is operated through its 81 19 Since the Company purchases its Gamma Knife units from Elekta, there are significant related party transactions with Elekta such as equipment purchases, commitments to purchase equipment, deposits for such equipment purchases, and costs to maintain the equipment. The Company believes that all its transactions with Elekta are arm’s-length transactions. At December 31, 2017, the Company had commitments to purchase two Cobalt-60 reloads from Elekta, as discussed in Note 11 – Commitments and Contingencies. The Company entered into a Purchase Agreement in 2014 to sell 650,000 1,600,000 1,000,000 200,000 100,000 220,000

ACCOUNTING POLICIES (Policies)

ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates in the preparation of financial statements
Advertising Costs, Policy [Policy Text Block]	Advertising costs 140,000 279,000 115,000
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted cash
Business Combinations And Credit Risk [Policy Text Block]	Business and credit risk All of the Company’s revenue was provided by twenty, eighteen, and seventeen customers in 2017, 2016, and, 2015, and these customers constitute accounts receivable at December 31, 2017 and 2016, respectively. One customer accounted for approximately 21%, 10%, and 10% of the Company’s total revenue in 2017, 2016 and 2015, respectively. At December 31, 2017 and 2016, three and two customers each accounted for more than 10% of total accounts receivable, respectively. The Company performs credit evaluations of its customers and generally does not require collateral. The Company has not experienced significant losses related to receivables from individual customers or groups of customers in any particular geographic area. All of the Company’s radiosurgery devices have been purchased through Elekta, to date. However, there are other manufacturers that also make radiosurgery devices. All of the Company’s revenue was provided by twenty, eighteen, and seventeen customers in 2017, 2016, and, 2015, and these customers constitute accounts receivable at December 31, 2017 and 2016, respectively. One customer accounted for approximately 21%, 10%, and 10% of the Company’s total revenue in 2017, 2016 and 2015, respectively. At December 31, 2017 and 2016, three and two customers each accounted for more than 10% of total accounts receivable, respectively. The Company performs credit evaluations of its customers and generally does not require collateral. The Company has not experienced significant losses related to receivables from individual customers or groups of customers in any particular geographic area. All of the Company’s radiosurgery devices have been purchased through Elekta, to date. However, there are other manufacturers that also make radiosurgery devices.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Accounts receivable and doubtful accounts
Non-controlling Interests [Policy Text Block]	Non-controlling interests
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment 3 10 The Company adopted a new accounting policy for the depreciation of PBRT property and equipment. Depreciation is determined using the modified units of production method, which is a function of both time and usage of the equipment. This depreciation method allocates costs considering the projected volume of usage through the useful life of the PBRT unit, which has been estimated at 20 The Company capitalizes interest incurred on property and equipment that is under construction, for which deposits or progress payments have been made. When a rate is not readily available, imputed interest is calculated using the Company’s incremental borrowing rate. The interest capitalized for property and equipment is the portion of interest cost incurred during the acquisition periods that could have been avoided if expenditures for the equipment had not been made. The Company capitalized interest of $ 138,000 443,000 431,000 The Company leases Gamma Knife and radiation therapy equipment to its customers under arrangements typically accounted for as operating leases. At December 31, 2017, the Company held equipment under operating lease contracts with customers with an original cost of $ 95,923,000 51,403,000 96,270,000 53,306,000 In April 2017, an existing customer exercised their option to purchase the Gamma Knife unit at its hospital at the end of the lease term for a predetermined purchase price, pursuant to the lease agreement. The lease terminated in April 2017, at which time, the unit was depreciated to the purchase price of the sale. Based on the guidance provided in ASC 360 Property, Plant and Equipment (“ASC 360”), the Company did not classify or measure the asset as held for sale prior to the lease termination, because the Gamma Knife unit was not available for immediate sale.
Investment, Policy [Policy Text Block]	Investment in equity securities – 0.46 0 579,000
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair value of financial instruments Level 1 Level 2 Level 3 Total Carrying December 31, 2017 Assets: Cash, cash equivalents, restricted cash $ 2,502 $ - $ - $ 2,502 $ 2,502 Investment in equity securities - - - - - Total $ 2,502 $ - $ - $ 2,502 $ 2,502 Liabilities Debt obligations $ - $ - $ 6,082 $ 6,082 $ 6,057 Total $ - $ - $ 6,082 $ 6,082 $ 6,057 December 31, 2016 Assets: Cash, cash equivalents, restricted cash $ 3,121 $ - $ - $ 3,121 $ 3,121 Investment in equity securities - - 579 579 579 Total $ 3,121 $ - $ 579 $ 3,700 $ 3,700 Liabilities Debt obligations $ - $ - $ 7,354 $ 7,354 $ 7,311 Total $ - $ - $ 7,354 $ 7,354 $ 7,311
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition - Rental income from medical services is recognized when services have been rendered and collectability is reasonably assured, on either a fee per use or revenue sharing basis. The terms of the contracts do not contain any guaranteed minimum payments. The Company’s contracts are typically for a ten year term and are classified as either fee per use or retail. Retail arrangements are further classified as either turn-key or revenue sharing. Rental income from fee per use contracts is determined by each hospital’s contracted rate. Rental income is recognized at the time the procedures are performed, based on each hospital’s contracted rate and the number of procedures performed. Under revenue sharing arrangements, the Company receives a contracted percentage of the reimbursement received by the hospital. The amount the Company expects to receive is recorded as revenue and estimated based on historical experience. Rental income estimates are reviewed periodically and adjusted as necessary. Under turn-key arrangements, the Company receives payment from the hospital in the amount of its reimbursement from third party payors, and the Company is responsible for paying all the operating costs of the equipment. Operating costs are determined primarily based on historical treatment protocols and cost schedules with the hospital. The Company records an estimate of operating costs which are reviewed on a regular basis and adjusted as necessary to more accurately reflect the actual operating costs. For turn-key sites, the Company also shares a percentage of net operating profit. The Company records an estimate of net operating profit based on estimated revenues, less estimated operating costs. The operating costs and estimated net operating profit are recorded as other direct operating costs in the consolidated statement of operations.
Compensation Related Costs, Policy [Policy Text Block]	Stock-based compensation
Cost of Sales, Policy [Policy Text Block]	Costs of revenue –
Selling, General and Administrative Expenses, Policy [Policy Text Block]	Sales and Marketing
Income Tax, Policy [Policy Text Block]	Income taxes
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Functional currency Foreign Currency Matters
Asset Retirement Obligations Policy [Policy Text Block]	Asset Retirement Obligations – Asset Retirement Obligations
Earnings Per Share, Policy [Policy Text Block]	Earnings per share 2017 2016 2015 Numerator for basic and diluted earnings (loss) per share $ 1,923,000 $ 930,000 $ (1,522,000) Denominator: Denominator for basic and diluted earnings (loss) per share – weighted-average shares 5,754,000 5,570,000 5,519,000 Effect of dilutive securities Employee stock options and restricted stock 130,000 13,000 - Denominator for diluted earnings (loss) per share – adjusted weighted- average shares 5,884,000 5,583,000 5,519,000 Earnings (loss) per common share- basic $ 0.33 $ 0.17 $ (0.28) Earnings (loss) per common share- diluted $ 0.33 $ 0.17 $ (0.28) In 2017, options outstanding to purchase 14,000 3.90 4,000 In 2016, options outstanding to purchase 581,000 2.43 3.15 4,000 In 2015, options outstanding to purchase 614,000 2.05 3.15 3,000 200,000 2.20
Segment Reporting, Policy [Policy Text Block]	Business segment information - Based on the guidance provided in accordance with ASC 280 Segment Reporting The Company did not have any international operations as of December 31, 2016, but the Company’s single-unit facility in Peru treated its first patient in July 2017. 2017 2016 2015 Medical services revenues Domestic 99 % 100 % 100 % Foreign 1 % 0 % 0 % Total 100 % 100 % 100 % 2017 2016 2015 Property and equipment, net Domestic 93 % 93 % 93 % Foreign 7 % 7 % 7 % Total 100 % 100 % 100 %
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long lived asset impairment
New Accounting Pronouncements, Policy [Policy Text Block]	Revenue from Contracts with Customers Technical Corrections and Improvements to Topic 606 Leases In January 2016, the FASB issued ASU No. 2016-01 Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, which requires lessees to recognize, for all leases, at the commencement date, a lease liability, and a right-of-use asset. Under the new guidance, lessor accounting is largely unchanged. The new guidance is effective for the Company on January 1, 2019. Early adoption is permitted. The Company is evaluating the effect that ASU 2016-02 will have on its consolidated financial statements and related disclosures. The Company performed an analysis to determine if its revenue agreements with customers fall under the scope of ASU 2016-02 or ASU 2014-09 and concluded that, other than with respect to the Company’s stand-alone facility in Lima, Peru, ASU 2016-02 applied. The Company believes it is following an appropriate timeline to allow for proper recognition, presentation, and disclosure upon adoption of ASU 2016-02. In March 2016, the FASB issued ASU No. 2016-09 Compensation – Stock Compensation (Topic 718) In June 2016, the FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2016, the FASB issued ASU No. 2016-15 Statement of Cash Flows (Topic 230) – Classification of Certain Cash Receipts and Cash Payments In November 2016, the FASB issued ASU No. 2016-18 Statement of Cash Flows – Restricted Cash 100,000 200,000 In May 2017, the FASB issued ASU No. 2017-09 Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting
Reclassification, Policy [Policy Text Block]	Reclassifications

ACCOUNTING POLICIES (Tables)

ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The estimated fair value of the Company’s assets and liabilities as of December 31, 2017 and December 31, 2016 were as follows (in thousands): Level 1 Level 2 Level 3 Total Carrying December 31, 2017 Assets: Cash, cash equivalents, restricted cash $ 2,502 $ - $ - $ 2,502 $ 2,502 Investment in equity securities - - - - - Total $ 2,502 $ - $ - $ 2,502 $ 2,502 Liabilities Debt obligations $ - $ - $ 6,082 $ 6,082 $ 6,057 Total $ - $ - $ 6,082 $ 6,082 $ 6,057 December 31, 2016 Assets: Cash, cash equivalents, restricted cash $ 3,121 $ - $ - $ 3,121 $ 3,121 Investment in equity securities - - 579 579 579 Total $ 3,121 $ - $ 579 $ 3,700 $ 3,700 Liabilities Debt obligations $ - $ - $ 7,354 $ 7,354 $ 7,311 Total $ - $ - $ 7,354 $ 7,354 $ 7,311
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table illustrates the computations of basic and diluted earnings per share for the years ended December 31, 2017, 2016 and 2015. 2017 2016 2015 Numerator for basic and diluted earnings (loss) per share $ 1,923,000 $ 930,000 $ (1,522,000) Denominator: Denominator for basic and diluted earnings (loss) per share – weighted-average shares 5,754,000 5,570,000 5,519,000 Effect of dilutive securities Employee stock options and restricted stock 130,000 13,000 - Denominator for diluted earnings (loss) per share – adjusted weighted- average shares 5,884,000 5,583,000 5,519,000 Earnings (loss) per common share- basic $ 0.33 $ 0.17 $ (0.28) Earnings (loss) per common share- diluted $ 0.33 $ 0.17 $ (0.28)
Schedule of Domestic and Foreign Break out Percentages [Table Text Block]	The following table provides a break out of domestic and foreign allocations of medical services revenues and net property and equipment: 2017 2016 2015 Medical services revenues Domestic 99 % 100 % 100 % Foreign 1 % 0 % 0 % Total 100 % 100 % 100 % 2017 2016 2015 Property and equipment, net Domestic 93 % 93 % 93 % Foreign 7 % 7 % 7 % Total 100 % 100 % 100 %

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment consists of the following: DECEMBER 31, 2017 2016 Medical equipment and facilities $ 95,923,000 $ 96,270,000 Office equipment 576,000 537,000 Deposits and construction in progress 1,658,000 6,073,000 Deposits towards purchase of proton beam systems 2,000,000 2,000,000 100,157,000 104,880,000 Accumulated depreciation (51,666,000) (53,549,000) Net property and equipment $ 48,491,000 $ 51,331,000

LONG-TERM DEBT (Tables)

LONG-TERM DEBT (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule of Maturities of Long-term Debt [Table Text Block]	The following are contractual maturities of long-term debt by year at December 31, 2017: Principal Interest Year ending December 31, 2018 $ 2,459,000 $ 301,000 2019 1,988,000 163,000 2020 1,146,000 61,000 2021 464,000 13,000 $ 6,057,000 $ 538,000

OBLIGATIONS UNDER CAPITAL LEA24

OBLIGATIONS UNDER CAPITAL LEASES (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	Future minimum lease payments, together with the present value of the net minimum lease payments under capital leases at December 31, 2017, are summarized as follows: Net Present Value of Minimum Lease Payments Year ending December 31, 2018 $ 6,113,000 2019 4,550,000 2020 3,280,000 2021 5,453,000 2022 629,000 Thereafter 719,000 Total capital lease payments 20,744,000 Less imputed interest 3,658,000 17,086,000 Less current portion 4,814,000 $ 12,272,000

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The components of the provision for income taxes as of December 31, 2017, 2016 and 2015 consist of the following: YEARS ENDED DECEMBER 31, 2017 2016 2015 Current: Federal $ 55,000 $ 24,000 $ 35,000 State 109,000 146,000 103,000 Total current 164,000 170,000 138,000 Deferred: Federal (1,335,000) 680,000 353,000 State 68,000 93,000 (57,000) Total deferred (1,267,000) 773,000 296,000 $ (1,103,000) $ 943,000 $ 434,000
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Significant components of the Company’s deferred tax liabilities and assets as of December 31, 2017 and 2016 are as follows: DECEMBER 31, 2017 2016 Deferred tax liabilities: Property and equipment $ (5,009,000) $ (7,595,000) Total deferred tax liabilities (5,009,000) (7,595,000) Deferred tax assets: Net operating loss carryforwards 1,421,000 2,783,000 Accruals and allowances 157,000 193,000 Tax credits 438,000 380,000 Other – net 186,000 200,000 Capital loss carryover 959,000 1,228,000 Total deferred tax assets 3,161,000 4,784,000 Valuation allowance (1,062,000) (1,365,000) Deferred tax assets net of valuation allowance 2,099,000 3,419,000 Net deferred tax liabilities $ (2,910,000) $ (4,176,000)
Condensed Financial Statements [Table Text Block]	These amounts are presented in the financial statements as follows: DECEMBER 31, 2017 2016 Deferred income taxes (non-current) $ (2,910,000) $ (4,176,000) $ (2,910,000) $ (4,176,000)
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The (benefit) provision for income taxes differs from the amount computed by applying the U.S. federal statutory tax rate ( 34 YEARS ENDED DECEMBER 31, 2017 2016 2015 Computed expected federal income tax $ 279,000 $ 637,000 $ (360,000) State income taxes, net of federal benefit 28,000 169,000 (55,000) Non-deductible expenses 41,000 42,000 40,000 Impact of US Tax Reform (1,546,000) - - Change in valuation allowance 180,000 25,000 792,000 Other (85,000) 70,000 17,000 $ (1,103,000) $ 943,000 $ 434,000

SHAREHOLDERS' EQUITY (Tables)

SHAREHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	Changes in restricted stock units, consisting primarily of annual automatic grants and deferred compensation to non-employee directors, under the Incentive Compensation Plans during 2017 are as follows: Restricted Stock Grant Date Intrinsic Value Outstanding at January 1, 2017 4,000 $ 2.25 $ - Granted 22,000 $ 3.47 $ - Vested (22,000) $ 4.06 $ - Forfeited - $ - $ - Outstanding at December 31, 2017 4,000 $ 3.77 $ -
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Changes in stock options outstanding under the Incentive Compensation Plans during 2017 are as follows: Weighted Weighted Average Average Remaining Aggregate Number Exercise Contractual Intrinsic Options of Options Price Term (Years) Value Balance at December 31, 2016 625,000 $ 2.85 4.25 Granted 27,000 $ 3.31 6.66 Exercised (4,000) $ 2.81 - Forfeited (33,000) $ 2.82 - Balance at December 31, 2017 615,000 $ 2.87 3.48 $ 22,000 Exercisable at December 31, 2017 395,000 $ 2.86 3.35 $ -
Schedule of Nonvested Share Activity [Table Text Block]	A summary of the status of the Company’s non-vested stock options as of December 31, 2017, and changes during the year ended December 31, 2017 is presented below: Weighted Average Number Grant-Date Nonvested Options of Options Fair Value Nonvested at December 31, 2016 321,000 $ 1.18 Granted 27,000 $ 1.50 Vested (117,000) $ 1.20 Forfeited (11,000) $ 1.27 Nonvested at December 31, 2017 220,000 $ 1.20
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of the Company’s option grants under the Plan in 2017, 2016 and 2015 was estimated using the following assumptions: 2017 2016 2015 Expected life (years) 7.0 7.0 7.0 Expected forfeiture rate 0.0 % 0.0 % 0.0 % Expected volatility 53 % 53 % 41 % Dividend yield 0 % 0 % 0 % Risk-free interest rate 2.0 % 2.0 % 2.0 %

OPERATING LEASES (Tables)

OPERATING LEASES (Tables)	12 Months Ended
	Dec. 31, 2017
Leases, Operating [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future minimum payments under non-cancelable operating leases, net of expected sublease income, having initial terms of more than one year consisted of the following: Year ending December 31, 2018 $ 266,000 2019 272,000 2020 245,000 2021 252,000 2022 259,000 Thereafter 165,000 $ 1,459,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Long-term Purchase Commitment [Table Text Block]	The Company estimates the following commitments for each of the equipment systems, with expected timing of payments as follows as of December 31, 2017: 2018 Thereafter Total Proton Beam Units $ - $ 25,800,000 $ 25,800,000 Gamma Knife Units 1,500,000 - 1,500,000 Total Commitments $ 1,500,000 $ 25,800,000 $ 27,300,000

BUSINESS AND BASIS OF PRESENT29

BUSINESS AND BASIS OF PRESENTATION (Details Textual)	Dec. 31, 2017
OR21 LLC [Member]
Equity Method Investment, Ownership Percentage	50.00%
Architectural Design Company [Member]
Equity Method Investment, Ownership Percentage	50.00%

ACCOUNTING POLICIES (Details)

ACCOUNTING POLICIES (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
ASSETS
Cash, cash equivalents, restricted cash, Carrying Value	$ 2,152,000	$ 2,871,000	$ 2,209,000	$ 1,059,000
Total, Carrying Value	58,176,000	60,598,000
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	2,502,000	3,121,000
Investment in equity securities, Fair Value	0	579,000
Total, Fair Value	2,502,000	3,700,000
Liabilities, Fair Value
Debt obligations, Fair Value	6,082,000	7,354,000
Total, Fair Value	6,082,000	7,354,000
Carrying Value [Member]
ASSETS
Cash, cash equivalents, restricted cash, Carrying Value	2,502,000	3,121,000
Investment in equity securities, Carrying Value	0	579,000
Total, Carrying Value	2,502,000	3,700,000
Liabilities, Carrying Value
Debt obligations, Carrying Value	6,057,000	7,311,000
Total, Carrying Value	6,057,000	7,311,000
Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	2,502,000	3,121,000
Investment in equity securities, Fair Value	0	0
Total, Fair Value	2,502,000	3,121,000
Liabilities, Fair Value
Debt obligations, Fair Value	0	0
Total, Fair Value	0	0
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	0	0
Investment in equity securities, Fair Value	0	0
Total, Fair Value	0	0
Liabilities, Fair Value
Debt obligations, Fair Value	0	0
Total, Fair Value	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	0	0
Investment in equity securities, Fair Value	0	579,000
Total, Fair Value	0	579,000
Liabilities, Fair Value
Debt obligations, Fair Value	6,082,000	7,354,000
Total, Fair Value	$ 6,082,000	$ 7,354,000

ACCOUNTING POLICIES (Details 1)

ACCOUNTING POLICIES (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Line Items]
Numerator for basic and diluted earnings (loss) per share	$ 1,923,000	$ 930,000	$ (1,522,000)
Denominator:
Denominator for basic and diluted earnings (loss) per share - weighted-average shares	5,754,000	5,570,000	5,519,000
Effect of dilutive securities
Employee stock options and restricted stock	130,000	13,000	0
Denominator for diluted earnings (loss) per share - adjusted weighted- average shares	5,884,000	5,583,000	5,519,000
Earnings (loss) per common share- basic	$ 0.33	$ 0.17	$ (0.28)
Earnings (loss) per common share- diluted	$ 0.33	$ 0.17	$ (0.28)

ACCOUNTING POLICIES (Details 2)

ACCOUNTING POLICIES (Details 2)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Medical Services Revenues [Member]
Accounting Policies [Line Items]
Break out, Percentage	100.00%	100.00%	100.00%
Property, Plant and Equipment [Member]
Accounting Policies [Line Items]
Break out, Percentage	100.00%	100.00%	100.00%
Domestic [Member] | Medical Services Revenues [Member]
Accounting Policies [Line Items]
Break out, Percentage	99.00%	100.00%	100.00%
Domestic [Member] | Property, Plant and Equipment [Member]
Accounting Policies [Line Items]
Break out, Percentage	93.00%	93.00%	93.00%
Foreign [Member] | Medical Services Revenues [Member]
Accounting Policies [Line Items]
Break out, Percentage	1.00%	0.00%	0.00%
Foreign [Member] | Property, Plant and Equipment [Member]
Accounting Policies [Line Items]
Break out, Percentage	7.00%	7.00%	7.00%

ACCOUNTING POLICIES (Details Te

ACCOUNTING POLICIES (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2015
Accounting Policies [Line Items]
Interest Costs Capitalized	$ 138,000	$ 443,000	$ 431,000
Property Subject to or Available for Operating Lease, Net, Total	95,923,000	96,270,000
Property Subject to or Available for Operating Lease, Accumulated Depreciation	$ 51,403,000	$ 53,306,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	14,000	581,000	614,000
Stock Options Exercise Price	$ 3.90
Warrants Issued With Promissory Notes During The Period			200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.20	$ 2.20
Advertising Expense	$ 140,000	$ 279,000	$ 115,000
Investments, Fair Value Disclosure, Total	$ 0
Sales Revenue, Net [Member]
Accounting Policies [Line Items]
Concentration Risk, Percentage	100.00%	100.00%	100.00%
Customer One [Member] | Sales Revenue, Net [Member]
Accounting Policies [Line Items]
Concentration Risk, Percentage	21.00%	10.00%	10.00%
Restricted Stock Units (RSUs) [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,000	4,000	3,000
Accounting Standards Update 2016-18 [Member] | Reclassification of Restricted Cash [Member]
Accounting Policies [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Operating Results	$ 100,000	$ 200,000
PBRT [Member]
Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	20 years
Mevion Medical Systems Inc [Member]
Accounting Policies [Line Items]
Cost Method Investment Interest Percentage	0.46%
Investments, Fair Value Disclosure, Total	$ 0	$ 579,000	$ 579,000	$ 600,000
Maximum [Member]
Accounting Policies [Line Items]
Stock Options Exercise Price		$ 3.15	$ 3.15
Maximum [Member] | Medical and Office equipment [Member]
Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Minimum [Member]
Accounting Policies [Line Items]
Stock Options Exercise Price		$ 2.43	$ 2.05
Minimum [Member] | Customer Two [Member] | Accounts Receivable [Member]
Accounting Policies [Line Items]
Concentration Risk, Percentage	10.00%	10.00%
Minimum [Member] | Customer Three [Member] | Accounts Receivable [Member]
Accounting Policies [Line Items]
Concentration Risk, Percentage	10.00%	10.00%
Minimum [Member] | Medical and Office equipment [Member]
Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	3 years

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 100,157,000	$ 104,880,000
Accumulated depreciation	(51,666,000)	(53,549,000)
Net property and equipment	48,491,000	51,331,000
Medical equipment and facilities [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	95,923,000	96,270,000
Accumulated depreciation	(16,777,000)	(16,642,000)
Office equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	576,000	537,000
Deposits and construction in progress [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,658,000	6,073,000
Deposits towards purchase of proton beam systems [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 2,000,000	$ 2,000,000

PROPERTY AND EQUIPMENT (Detai35

PROPERTY AND EQUIPMENT (Details Textual) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 51,666,000	$ 53,549,000
Property, Plant and Equipment, Net, Total	48,491,000	51,331,000
Construction in Progress, Gross	1,658,000
Medical Equipment and Facilities [Member]
Property, Plant and Equipment [Line Items]
Capital Leased Assets, Gross	44,758,000	43,703,000
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	16,777,000	$ 16,642,000
Radiation Oncology Physician Group [Member]
Property, Plant and Equipment [Line Items]
Long Term Purchase Commitment Deposits For Assets	400,000
Three Mevion S250 Proton Beam Radiation Therapy [Member]
Property, Plant and Equipment [Line Items]
Long Term Purchase Commitment Deposits For Assets	2,000,000
Gamma Knife Units [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Net, Total	$ 729,000

INVESTMENT IN EQUITY SECURITI36

INVESTMENT IN EQUITY SECURITIES (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Schedule of Cost-method Investments [Line Items]
Investments, Fair Value Disclosure		$ 0
Other than Temporary Impairment Losses, Investments		579,000	$ 0	$ 2,140,000
Cost-method Investments, Other than Temporary Impairment				26,000
Mevion Medical Systems Inc [Member]
Schedule of Cost-method Investments [Line Items]
Investments, Fair Value Disclosure	$ 600,000	0	579,000	579,000
Other than Temporary Impairment Losses, Investments	$ 2,114,000			$ 2,140,000
Cost Method Investments		$ 579,000	$ 579,000
Cost Method Investments Ownership Percentage		0.46%

LONG-TERM DEBT (Details)

LONG-TERM DEBT (Details)	Dec. 31, 2017USD ($)
Principal
2,018	$ 2,459,000
2,019	1,988,000
2,020	1,146,000
2,021	464,000
Long-term Debt	6,057,000
Interest
2,018	301,000
2,019	163,000
2,020	61,000
2,021	13,000
Interest	$ 538,000

LONG-TERM DEBT (Details Textual

LONG-TERM DEBT (Details Textual)	12 Months Ended
	Dec. 31, 2017USD ($)
Debt Instrument [Line Items]
Long-term Debt, Description	These notes are payable in 36 to 81 fully amortizing monthly installments, mature between December 2018 and November 2021
Gamma Knife Units [Member]
Debt Instrument [Line Items]
Debt Instrument, Collateral Amount	$ 15,125,000
Maximum [Member]
Debt Instrument [Line Items]
Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate	7.48%
Minimum [Member]
Debt Instrument [Line Items]
Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate	3.95%

OBLIGATIONS UNDER CAPITAL LEA39

OBLIGATIONS UNDER CAPITAL LEASES (Details)	Dec. 31, 2017USD ($)
Capital Lease Obligations [Line Items]
2,018	$ 6,113,000
2,019	4,550,000
2,020	3,280,000
2,021	5,453,000
2,022	629,000
Thereafter	719,000
Total capital lease payments	20,744,000
Less imputed interest	3,658,000
Gross Minimum Lease Payments	17,086,000
Less current portion	4,814,000
Net Minimum Lease Payments	$ 12,272,000

OBLIGATIONS UNDER CAPITAL LEA40

OBLIGATIONS UNDER CAPITAL LEASES (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Capital Lease Obligations [Line Items]
Capital Lease Obligations	$ 27,981,000	$ 27,061,000
Description of Lessee Leasing Arrangements, Capital Leases	payable in 41 to 84 monthly installments, and mature between September 2018 and October 2024.
Maximum [Member]
Capital Lease Obligations [Line Items]
Capital Lease Obligation Interest Rate	13.00%
Minimum [Member]
Capital Lease Obligations [Line Items]
Capital Lease Obligation Interest Rate	4.73%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current:
Federal	$ 55,000	$ 24,000	$ 35,000
State	109,000	146,000	103,000
Total current	164,000	170,000	138,000
Deferred:
Federal	(1,335,000)	680,000	353,000
State	68,000	93,000	(57,000)
Total deferred	(1,267,000)	773,000	296,000
Income Tax Expense (Benefit)	$ (1,103,000)	$ 943,000	$ 434,000

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Deferred tax liabilities:
Property and equipment	$ (5,009,000)	$ (7,595,000)
Total deferred tax liabilities	(5,009,000)	(7,595,000)
Deferred tax assets:
Net operating loss carryforwards	1,421,000	2,783,000
Accruals and allowances	157,000	193,000
Tax credits	438,000	380,000
Other - net	186,000	200,000
Capital loss carryover	959,000	1,228,000
Total deferred tax assets	3,161,000	4,784,000
Valuation allowance	(1,062,000)	(1,365,000)
Deferred tax assets net of valuation allowance	2,099,000	3,419,000
Net deferred tax liabilities	$ (2,910,000)	$ (4,176,000)

INCOME TAXES (Details 2)

INCOME TAXES (Details 2) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Line Items]
Deferred income taxes (non-current)	$ (2,910,000)	$ (4,176,000)
Total deferred tax liabilities	$ 2,910,000	$ 4,176,000

INCOME TAXES (Details 3)

INCOME TAXES (Details 3) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Line Items]
Computed expected federal income tax	$ 279,000	$ 637,000	$ (360,000)
State income taxes, net of federal benefit	28,000	169,000	(55,000)
Non-deductible expenses	41,000	42,000	40,000
Impact of US Tax Reform	(1,546,000)	0	0
Change in valuation allowance	180,000	25,000	792,000
Other	(85,000)	70,000	17,000
Income Tax Expense (Benefit)	$ (1,103,000)	$ 943,000	$ 434,000

INCOME TAXES (Details Textual)

INCOME TAXES (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Line Items]
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent		34.00%	34.00%	34.00%
Deferred Tax Assets, Operating Loss Carryforwards, Domestic		$ 5,928,000
Deferred Tax Assets, Operating Loss Carryforwards, State and Local		$ 1,137,000
Net Operating Loss Carry Forwards And Other Deferred Tax Assets Percentage		50.00%
Operating Loss Carry Forward Expiration Dates		expire between 2024 and 2034
Income Tax Expense (Benefit)		$ (1,103,000)	$ 943,000	$ 434,000
Increase (Decrease) in Income Taxes				0
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		$ 303,000	$ 25,000	$ 792,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		34.00%
Income Tax Reconciliation Change In Net Effect In Tax Rate		$ 1,546,000
Scenario, Plan [Member]
Income Tax Disclosure [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
State and Local Jurisdiction [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, State and Local		177,000
Foreign Tax Authority [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Domestic		3,895,000
Domestic Tax Authority [Member]
Income Tax Disclosure [Line Items]
Operating Loss Carryforwards		$ 370,000

SHAREHOLDERS' EQUITY (Details)

SHAREHOLDERS' EQUITY (Details) - $ / shares	Jan. 04, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested, Number of Options, Outstanding		321,000
Restricted Stock Units, Granted	161,766
Restricted Stock Units, Vested		(117,000)
Restricted Stock Units, Forfeited		(11,000)
Nonvested, Number of Options, Outstanding		220,000	321,000
Weighted Average Grant-Date Fair Value, Nonvested, Outstanding		$ 1.18
Grant Date Weighted-Average Fair Value, Granted		1.5	$ 0.97	$ 1.15
Grant Date Weighted-Average Fair Value, Vested		1.2
Grant Date Weighted-Average Fair Value, Forfeited		1.27
Weighted Average Grant-Date Fair Value, Nonvested, Outstanding		$ 1.2	$ 1.18
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested, Number of Options, Outstanding		4,000
Restricted Stock Units, Granted		22,000
Restricted Stock Units, Vested		(22,000)
Restricted Stock Units, Forfeited		0
Nonvested, Number of Options, Outstanding		4,000	4,000
Weighted Average Grant-Date Fair Value, Nonvested, Outstanding		$ 2.25
Grant Date Weighted-Average Fair Value, Granted		3.47
Grant Date Weighted-Average Fair Value, Vested		4.06
Grant Date Weighted-Average Fair Value, Forfeited		0
Weighted Average Grant-Date Fair Value, Nonvested, Outstanding		3.77	$ 2.25
Intrinsic Value, Outstanding		0
Intrinsic Value, Granted		0
Intrinsic Value, Vested		0
Intrinsic Value, Forfeited		0
Intrinsic Value, Outstanding		$ 0	$ 0

SHAREHOLDERS' EQUITY (Details 1

SHAREHOLDERS' EQUITY (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning balance	625,000
Number of Options, Granted	27,000
Number of Options, Exercised	(4,000)
Number of Options, Forfeited	(33,000)
Number of Options, Ending balance	615,000
Number of Options, Exercisable at December 31, 2016	395,000
Weighted Average Exercise Price, Beginning balance	$ 2.85
Weighted Average Exercise Price, Granted	3.31
Weighted Average Exercise Price - Exercised	2.81
Weighted Average Exercise Price, Forfeited	2.82
Weighted Average Exercise Price, Ending balance	2.87
Weighted Average Exercise Price, Exercisable at December 31, 2016	$ 2.86
Weighted Average Remaining Contractual Term (Years)	3 years 5 months 23 days	4 years 3 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term	6 years 7 months 28 days
Weighted Average Remaining Contractual Term (Years), Exercisable at December 31, 2016	3 years 4 months 6 days
Aggregate Intrinsic Value, Balance at December 31, 2016	$ 22,000
Aggregate Intrinsic Value, Exercisable at December 31, 2016	$ 0

SHAREHOLDERS' EQUITY (Details 2

SHAREHOLDERS' EQUITY (Details 2) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Shareholders Equity [Line Items]
Nonvested, Number of Options, Outstanding	321,000
Number of Options, Granted	27,000
Nonvested, Number of Options, Vested	(117,000)
Nonvested, Number of Options, Forfeited	(11,000)
Nonvested, Number of Options, Outstanding	220,000	321,000
Weighted Average Grant-Date Fair Value, Nonvested, Outstanding	$ 1.18
Weighted Average Grant-Date Fair Value, Nonvested, Granted	1.5	$ 0.97	$ 1.15
Weighted Average Grant-Date Fair Value, Nonvested, Vested	1.2
Weighted Average Grant-Date Fair Value, Nonvested, Forfeited	1.27
Weighted Average Grant-Date Fair Value, Nonvested, Outstanding	$ 1.2	$ 1.18

SHAREHOLDERS' EQUITY (Details 3

SHAREHOLDERS' EQUITY (Details 3)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (years)	7 years	7 years	7 years
Expected forfeiture rate	0.00%	0.00%	0.00%
Expected volatility	53.00%	53.00%	41.00%
Dividend yield	0.00%	0.00%	0.00%
Risk-free interest rate	2.00%	2.00%	2.00%

SHAREHOLDERS' EQUITY (Details T

SHAREHOLDERS' EQUITY (Details Textual) - USD ($)	Jan. 04, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2010	Dec. 31, 2001
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 1.5	$ 0.97	$ 1.15
Stock Repurchase Program, Number of Shares Authorized to be Repurchased						1,000,000
Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased		72,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 434,000
Allocated Share-based Compensation Expense	$ 108,000	$ 144,000	$ 139,000	$ 138,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		117,000
Class of Warrant or Right, Outstanding		0	100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.20	$ 2.20
Class of Warrant or Right, Exercised		100,000	100,000
Noncash Warrants Exercised		50,000
Stock Issued During Period, Shares, Warrants Exercised		25,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		4,000
Proceeds from Stock Options Exercised		$ 6,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	161,766
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number		220,000	321,000
Restricted Stock [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		237,000
Performance Share Award Agreement [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number		129,000
Non Vested Shares [Member]
Class of Stock [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		$ 297,000
Share-based Compensation Award, Tranche One [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		2,000
Employee [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services		10,000
Incentive Compensation Plan [Member]
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance					1,630,000
Provision For Reduction Of Reserved Shares					1.59
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award		2,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		241,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		5 years
Share Based Compensation Arrangement By Share Based Payment Award Remaining Number Of Shares Available For Grant		375,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 15,000	$ 8,000	$ 7,000
Employee Benefits and Share-based Compensation, Total		11,000
Offsetting Tax Benefit		4,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		$ 8,000
Weighted Average Number of Shares, Restricted Stock		4,000	4,000	3,000
Incentive Compensation Plan [Member] | Non Employee Directors [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		500
Incentive Compensation Plan [Member] | Non Employee Directors and Corporate Secretary [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		34,000
Retainer Fees [Member]
Class of Stock [Line Items]
Employee Benefits and Share-based Compensation, Total		$ 60,000
Retainer Fees [Member] | Incentive Compensation Plan [Member] | Non Employee Directors [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		197,000

RETIREMENT PLAN (Details Textua

RETIREMENT PLAN (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	4.00%
Defined Contribution Plan, Cost Recognized	$ 30,000	$ 27,000	$ 27,000

OPERATING LEASES (Details)

OPERATING LEASES (Details)	Dec. 31, 2017USD ($)
Operating Leased Assets [Line Items]
2,018	$ 266,000
2,019	272,000
2,020	245,000
2,021	252,000
2,022	259,000
Thereafter	165,000
Total Future Minimum Payments Due	$ 1,459,000

OPERATING LEASES (Details Textu

OPERATING LEASES (Details Textual) - USD ($)	Aug. 13, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2013
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense		$ 308,000	$ 307,000	$ 175,000
Operating Leases Cumulative Loss					$ 115,000
Operating Leases, Rent Expense, Net		$ 0	$ 76,000	$ 191,000
Lease Expiration Period	7 years

COMMITMENTS AND CONTINGENCIES54

COMMITMENTS AND CONTINGENCIES (Details)	Dec. 31, 2017USD ($)
Long-term Purchase Commitment [Line Items]
2,018	$ 1,500,000
Thereafter	25,800,000
Total	27,300,000
Proton Beam Unit [Member]
Long-term Purchase Commitment [Line Items]
2,018	0
Thereafter	25,800,000
Total	25,800,000
Gamma Knife Units [Member]
Long-term Purchase Commitment [Line Items]
2,018	1,500,000
Thereafter	0
Total	$ 1,500,000

COMMITMENTS AND CONTINGENCIES55

COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Aug. 04, 2017
Gamma Knife Perfexion System [Member]
Commitments And Contingencies [Line Items]
Long-term Purchase Commitment, Amount	$ 1,500,000
Mevion Medical Systems Inc [Member]
Commitments And Contingencies [Line Items]
Long-term Purchase Commitment, Amount	25,800,000
Long-term Purchase Commitment, Deposits for Future Purchase	$ 2,000,000
Prepaid Contract Expenses		$ 1,000,000

NOTE, WARRANT, & COMMON STOCK56

NOTE, WARRANT, & COMMON STOCK PURCHASE AGREEMENT (Details Textual) - USD ($)	Jun. 12, 2014	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Oct. 31, 2014
Note, Warrant And Common Stock Purchase Agreement [Line Items]
Common Stock, Shares, Issued		5,710,000	5,468,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.20	$ 2.20
Proceeds from Issuance of Private Placement	$ 1,600,000
Gain (Loss) on Extinguishment of Debt		$ 0	$ (108,000)	$ 0
Class of Warrant or Right, Exercised		100,000	100,000
Class of Warrant or Right, Outstanding		0	100,000
Notes Payable [Member]
Note, Warrant And Common Stock Purchase Agreement [Line Items]
Warrants Not Settleable in Cash, Fair Value Disclosure			$ 145,000
Gain (Loss) on Extinguishment of Debt			108,000
Debt Instrument, Unamortized Discount			80,000
Deferred Fees From Issuance Of Note			$ 28,000
Private Placement [Member]
Note, Warrant And Common Stock Purchase Agreement [Line Items]
Sale of Stock, Number of Shares Issued in Transaction		100,000
Proceeds from Issuance of Private Placement		$ 220,000
Common Stock, Value, Subscriptions		1,220,000
Note and Warrant Purchase Agreement [Member]
Note, Warrant And Common Stock Purchase Agreement [Line Items]
Debt Instrument, Face Amount		$ 1,000,000			$ 1,000,000
Common Stock, Shares, Issued		200,000			200,000
Debt Instrument, Interest Rate, Stated Percentage					15.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 2.20
Mevion Medical Systems Inc [Member]
Note, Warrant And Common Stock Purchase Agreement [Line Items]
Cash Payments		$ 1,000,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Textual) - USD ($)	Jun. 12, 2014	Dec. 31, 2017	Dec. 31, 2016	Oct. 31, 2014
Related Party Transaction [Line Items]
Common Stock, Shares, Issued		5,710,000	5,468,000
Proceeds from Issuance of Private Placement	$ 1,600,000
Note and Warrant Purchase Agreement [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount		$ 1,000,000		$ 1,000,000
Common Stock, Shares, Issued		200,000		200,000
Private Placement [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues	650,000
Sale of Stock, Number of Shares Issued in Transaction		100,000
Proceeds from Issuance of Private Placement		$ 220,000
GKF Subsidiary [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent		81.00%
U.S. Subsidiary Of Elekta [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent		19.00%